

**eMethods.** Search strategies for PubMed, EMBASE, Web ofScience, Cochrane database.

**Table S1.** Joanna Brigg's Institute assessment of study bias.

**Table S2.** Incidence of TEAEs by grade in studies evaluating BsAbs for R/R LBCL after CAR-T therapy failure.

**Figure S1.** Publication bias and sensitivity analyses for pooled ORR and CR of BsAbs in R/R LBCL after CAR-T therapy failure: Funnel plot for ORR (A) and CR (C); Leave-one-out sensitivity analysis for ORR (B) and CR (D).

**Figure S2.** Pooled overall (A) and complete (B) response rates of BsAbs in CAR-T - refractory patients with R/R LBCL.

**Figure S3.** Comparison of pooled CR among different BsAbs in patients with R/R LBCL after CAR-T therapy failure.

**Figure S4.** Comparison of pooled response rates between intravenous and subcutaneous administration of BsAbs in patients with R/R LBCL after CAR-T therapy failure: (A) ORR; (B) CR.

**Figure S5.** Pooled incidence of TEAEs associated with BsAbs in patients with R/R LBCL after CAR-T therapy failure: (A) any-grade TEAEs; (B) grade  $\geq 3$  TEAEs; (C) any-grade CRS; (D) any-grade infections; (E) grade  $\geq 3$  infections; (F) grade  $\geq 3$  neutropenia; (G) grade  $\geq 3$  anemia.

**eMethods.** Search strategies for PubMed, EMBASE, Web of Science, Cochrane database.

(1)Pubmed

No	Search	Results
#1	Lymphoma[Mesh]	193840
#2	(((Lymphomas[Title/Abstract]) OR (Lymphoma, Malignant[Title/Abstract])) OR (Lymphomas, Malignant[Title/Abstract])) OR (Malignant Lymphoma[Title/Abstract])) OR (Malignant Lymphomas[Title/Abstract])	59369
#3	("Lymphoma"[Mesh]) OR (((Lymphomas[Title/Abstract]) OR (Lymphoma, Malignant[Title/Abstract])) OR (Lymphomas, Malignant[Title/Abstract])) OR (Malignant Lymphoma[Title/Abstract])) OR (Malignant Lymphomas[Title/Abstract])) Sort by: Most Recent	211130
#4	"Antibodies, Bispecific"[Mesh]	4967
#5	((((((((Bifunctional Antibodies[Title/Abstract]) OR (Antibodies, Bifunctional[Title/Abstract])) OR (Bispecific Antibodies[Title/Abstract])) OR (Bispecific Monoclonal Antibodies[Title/Abstract])) OR (Antibodies, Bispecific Monoclonal[Title/Abstract])) OR (Monoclonal Antibodies, Bispecific[Title/Abstract])) OR (epcoritamab[Title/Abstract])) OR (glofitamab[Title/Abstract])) OR (mosunetuzumab[Title/Abstract])) OR (odronextamab[Title/Abstract])	5596
#6	("Antibodies, Bispecific"[Mesh]) OR (((((((((((Bifunctional Antibodies[Title/Abstract]) OR (Antibodies, Bifunctional[Title/Abstract])) OR (Bispecific Antibodies[Title/Abstract])) OR (Bispecific Monoclonal Antibodies[Title/Abstract])) OR (Antibodies, Bispecific Monoclonal[Title/Abstract])) OR (Monoclonal Antibodies, Bispecific[Title/Abstract])) OR (epcoritamab[Title/Abstract])) OR (glofitamab[Title/Abstract])) OR (mosunetuzumab[Title/Abstract])) OR (odronextamab[Title/Abstract]))	8331
#7	(((("clinical trial, phase ii"[Publication Type]) OR ("clinical trial, phase iii"[Publication Type]) OR "clinical trial, phase i"[Publication Type]) OR phase I[Title/Abstract] OR (phase II[Title/Abstract] OR phase III[Title/Abstract] OR phase 1[Title/Abstract] OR phase 2[Title/Abstract] OR phase 3[Title/Abstract])) OR (clinicaltrials.gov)	364875
#8	#1or#2)And(#4or#5)And#7	123

## (2) Embase

No	Search	Results
#1	lymphoma'/exp OR 'lymphoma'	504,667
#2	lymphomas':ab,ti OR 'lymphoma, malignant':ab,ti OR 'lymphomas, malignant':ab,ti OR 'malignant lymphoma':ab,ti OR 'malignant lymphomas':ab,ti	86390
#3	#1or#2	510,960
#4	bispecific antibody'/exp OR 'bispecific antibody'	9615
#5	antibodies, bispecific':ab,ti OR 'bifunctional antibodies':ab,ti OR 'antibodies, bifunctional':ab,ti OR 'bispecific antibodies':ab,ti OR 'bispecific monoclonal antibodies':ab,ti OR 'antibodies, bispecific monoclonal':ab,ti OR 'monoclonal antibodies, bispecific':ab,ti OR 'epcoritamab':ab,ti OR 'glofitamab':ab,ti OR 'mosunetuzumab':ab,ti OR 'odronextamab':ab,ti	4888
#6	#4or#5	10723
#7	phase 2 clinical trial'/exp OR 'phase 1 clinical trial'/exp OR 'phase 3 clinical trial'/exp OR 'phase ii':ab,ti OR 'phase i':ab,ti OR 'phase iii':ab,ti OR 'phase 2':ab,ti OR 'phase 1':ab,ti OR 'phase 3':ab,ti OR clinicaltrials.gov	741874
#8	#3and#6and#7	953

## (3) Web of science

No	Search	Results
#1	(((((TS=("Lymphoma")) OR TS=("Lymphomas")) OR TS=("Lymphoma, Malignant")) OR TS=("Lymphomas, Malignant")) OR TS=("Malignant Lymphoma")) OR TS=("Malignant Lymphomas"))	530158
#2	(((((((((TS=("Antibodies, Bispecific")) OR TS=("Bifunctional Antibodies")) OR TS=("Antibodies, Bifunctional")) OR TS=("Bispecific Antibodies")) OR TS=("Bispecific Monoclonal Antibodies")) OR TS=("Antibodies, Bispecific Monoclonal")) OR TS=("Monoclonal Antibodies, Bispecific")) OR TS=("epcoritamab")) OR TS=("glofitamab")) OR TS=("mosunetuzumab")) OR TS=("odronextamab"))	9276
#3	(((((((((TS=("clinical trial, phase i")) OR TS=("clinical trial, phase ii")) OR TS=("clinical trial, phase iii")) OR TS=("phase I")) OR TS=("phase II")) OR TS=("phase III")) OR TS=("phase 1")) OR TS=("phase 2")) OR TS=("phase 3")) OR TS=("clinicaltrials.gov"))	704058
#4	#1 AND #2 AND #3	708


## (4) Cochrane Library

No	Search	Results
#1	MeSH descriptor: [Lymphoma] explode all trees	4629
#2	(Lymphomas):ab,ti,kw OR (Lymphoma, Malignant):ab,ti,kw OR (Lymphomas, Malignant):ab,ti,kw OR (Malignant Lymphoma):ab,ti,kw OR (Malignant Lymphomas):ab,ti,kw	2769
#3	#1 OR #2	6589
#4	MeSH descriptor: [Antibodies, Bispecific] explode all trees	123
#5	(Bifunctional Antibodies):ab,ti,kw OR (Antibodies, Bifunctional):ab,ti,kw OR (Bispecific Antibodies):ab,ti,kw OR (Bispecific Monoclonal Antibodies):ab,ti,kw OR (Antibodies, Bispecific Monoclonal):ab,ti,kw OR (Monoclonal Antibodies, Bispecific):ab,ti,kw OR (epcoritamab):ab,ti,kw OR (glofitamab):ab,ti,kw OR (mosunetuzumab):ab,ti,kw OR (odronextamab):ab,ti,kw	316
#6	#4 OR #5	316
#7	MeSH descriptor: [Clinical Trial] explode all trees	42
#8	(clinical trial, phase i):ab,ti,kw OR (clinical trial, phase ii):ab,ti,kw OR (clinical trial, phase iii):ab,ti,kw OR (phase I):ab,ti,kw OR (phase II):ab,ti,kw OR (phase III):ab,ti,kw OR (phase 1):ab,ti,kw OR (phase 2):ab,ti,kw OR (phase 3):ab,ti,kw OR (clinicaltrials.gov):ab,ti,kw	251369
#9	#7 OR #8	251411
#10	#3 AND #6 AND #9	44






**Figure S1.** Publication bias and sensitivity analyses for pooled ORR and CR of BsAbs in R/R LBCL after CAR-T therapy failure: Funnel plot for ORR (A) and CR (C); Leave-one-out sensitivity analysis for ORR (B) and CR (D).




**Figure S2.** Pooled overall (A) and complete (B) response rates of BsAbs in CAR-T – refractory patients with R/R LBCL.


**A**




**B**



**Figure S3.** Comparison of pooled CR among different BsAbs in patients with R/R LBCL after CAR-T therapy failure.



**Figure S4.** Comparison of pooled response rates between intravenous and subcutaneous administration of BsAbs in patients with R/R LBCL after CAR-T therapy failure: (A) ORR; (B) CR.



**Figure S5.** Pooled incidence of TEAEs associated with BsAbs in patients with R/R LBCL after CAR-T therapy failure: (A) any-grade TEAEs; (B) grade  $\geq 3$  TEAEs; (C) any-grade CRS; (D) any-grade infections; (E) grade  $\geq 3$  infections; (F) grade  $\geq 3$  neutropenia; (G) grade  $\geq 3$  anemia.

